Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Expert Financial Analysis and Reporting

Neuralstem: Update on Phase I Trial of Neural Stem Cells in ALS is Encouraging (CUR, $1.45)

Purpose of Report
An encouraging update on the phase I trial of Neuralstem's (CUR) neural stem cells in ALS was just…
Read more…